Since the role of BCAT1 overexpression in glioma development was reported in 2013 [40], BCAT1 has received increasing attention as a prognostic tumour marker and an attractive target for cancer therapy in many types of tumours [27]. This evidence concerns the gene BCAT1 and glioma.